Pagani O, Regan MM, Fleming GF, et al. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. SABCS 2017, GS4-02.
Fase IIB-studie van start bij uitgezaaide prostaatkanker: neemt effectiviteit taxanen toe in combinatie met darolutamide?
mrt 2024 | Uro-oncologie